Research Topics
Species | Fernando CabanillasSummaryAffiliation: The University of Texas Country: USA Publications
| Collaborators
|
Detail Information
Publications
Vitamin C and cancer: what can we conclude--1,609 patients and 33 years later?Fernando Cabanillas
University of Puerto Rico School of Medicine, San Juan, Puerto Rico
P R Health Sci J 29:215-7. 2010..Nor do we know which histological types of cancers, if any, are susceptible to this agent. Finally, we don't know what the recommended dose of Vitamin C is, if there is indeed such a dose, that can produce an anti-tumor response...
Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as supportFernando Cabanillas
Auxilio Cancer Center, Auxilio Mutuo Hospital, San Juan, 00927 Puerto Rico
Leuk Lymphoma 53:1929-33. 2012..The results with R-CHOP-GM-CSF every 14 days are encouraging, and merit a prospective comparative clinical trial against R-CHOP-14 in order to elucidate the contribution of GM-CSF...
Rectal adenocarcinoma: proposal for a model based on pretreatment prognostic factorsFernando Cabanillas
University of Puerto Rico School of Medicine, San Juan, Puerto Rico
P R Health Sci J 31:52-8. 2012..The present study aimed to determine pre-treatment prognostic factors that are associated with an unfavorable outcome...- New developments in the field of diffuse large cell lymphomaFernando Cabanillas
Auxilio Cancer Center, Hospital Auxilio Mutuo, San Juan, Puerto Rico 00927, USA
Hematology 17:S98-100. 2012..New entities such as breast implant associated anaplastic large cell lymphoma will be described... - High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complicationF Cabanillas
Auxilio Mutuo Cancer Center, Hospital Auxilio Mutuo, San Juan, Puerto Rico
Ann Oncol 17:1424-7. 2006..Rituximab is associated with low incidence of hypogammaglobulinemia and little morbidity. Our experience with the combination of rituximab + chemotherapy suggested the opposite... - Front-line management of diffuse large B cell lymphomaFernando Cabanillas
Department of Medicine, University of Puerto Rico School of Medicine, Centro de Cancer, Auxilio Mutuo, San Juan, Puerto Rico
Curr Opin Oncol 22:642-5. 2010..The purpose of this review is to discuss the pertinent advances and to highlight areas of consensus and controversy... - Non-Hodgkin's lymphoma: the old and the newFernando Cabanillas
Auxilio Cancer Center, San Juan, PR, USA
Clin Lymphoma Myeloma Leuk 11:S87-90. 2011..Their future role in front-line management remains to be determined... - Dose dense CHOP: when more is not always better!Fernando Cabanillas
Auxilio Mutuo Cancer Center, San Juan, Puerto Rico
Leuk Lymphoma 48:845-6. 2007 - BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcomeGeorge Z Rassidakis
Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Clin Cancer Res 8:488-93. 2002..Therefore, we correlated BAX expression with presenting features and clinical outcome in untreated patients with HD... - Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemiaDeborah A Thomas
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 106:120-7. 2006..In animal models, the encapsulation of vincristine into sphingomyelin liposomes or "sphingosomes" for injection (SV) has improved efficacy compared with conventional vincristine... - A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphomaChul S Ha
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 63:188-93. 2005..MR was defined as disappearance of t(14;18) (q32;q21) amplified by polymerase chain reaction (PCR)... - BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimensGeorge Z Rassidakis
Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston 77030, USA
Blood 100:3935-41. 2002..We conclude that BCL-2 is frequently expressed by HRS cells in cHD and is associated with inferior FFS in patients treated with ABVD or equivalent regimens... - Central lymphatic irradiation for stage I-III follicular lymphoma: report from a single-institutional prospective studyChul S Ha
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
Int J Radiat Oncol Biol Phys 57:316-20. 2003..This study was undertaken to update our experience with follicular lymphoma treated with central lymphatic irradiation (CLI)... - Molecular response of follicular lymphoma to cyclophosphamide, doxorubicin, vincristine, prednisone C(H)OP or COP-based therapy as measured by polymerase chain reaction evidence of translocation (14;18)(q32;q21)Chul S Ha
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA
Cancer J 10:49-53. 2004..This study was undertaken to study the molecular response rate of follicular lymphoma to C(H)OP-based therapy and to analyze prognostic factors for molecular response... - Outcome with the hyper-CVAD regimens in lymphoblastic lymphomaDeborah A Thomas
Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
Blood 104:1624-30. 2004..Other modifications of the program could include incorporation of monoclonal antibodies and/or nucleoside analogs, particularly for slow responders or those with residual mediastinal disease... - Establishment and characterization by gene expression profiling of a new diffuse large B-cell lymphoma cell line, EJ-1, carrying t(14;18) and t(8;14) translocationsAndre Goy
Departments of Lymphoma, The University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
Lab Invest 83:913-6. 2003 - Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphomaAndre Goy
Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 459, Houston, TX 77030, USA
J Clin Oncol 23:667-75. 2005..Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma... - The role of mitoxantrone in the treatment of indolent lymphomasFredrick Hagemeister
The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
Oncologist 10:150-9. 2005..Because cure remains elusive in patients with indolent lymphoma, maximum prolongation of PFS with minimal toxicity and maximum preservation of quality of life should remain central goals of treatment... - Stage III follicular lymphoma: long-term follow-up and patterns of failureChul S Ha
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 57:748-54. 2003..To analyze the long-term outcomes and pattern of failures for Stage III follicular lymphomas... - Establishment and characterization of a new mantle cell lymphoma cell line M-1Andre Goy
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Leuk Lymphoma 45:1255-60. 2004..The characterization of a new mantle cell lymphoma cell line is a unique tool for studying the biology of this subtype of lymphoma for which only a few cell lines have been established... - Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphomaJorge E Romaguera
Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Cancer 97:586-91. 2003..The impact of endoscopic assessment on the management of MCL patients is unknown... - Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical debulking for patients with bulky, aggressive lymphomaRichard B Wilder
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Cancer 94:601-5. 2002.... - European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin diseaseRichard B Wilder
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Cancer 94:1731-8. 2002.... - International prognostic index-based outcomes for diffuse large B-cell lymphomasRichard B Wilder
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Cancer 94:3083-8. 2002..We present the results of doxorubicin-based chemotherapy with or without involved-field radiotherapy for patients with diffuse large B-cell lymphoma (DLBCL) according to the international prognostic index (IPI)... - Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancerDavid R Fogelman
M D Anderson Cancer Center, Houston, TX 77030, USA
Anticancer Res 31:1417-20. 2011..This case highlights the potential benefit for PARP inhibition in BRCA2-related pancreatic cancer... - Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphomaJorge E Romaguera
Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX, USA
Br J Haematol 150:200-8. 2010..We conclude that intense chemoimmunotherapy without stem cell transplantation is effective for untreated aggressive MCL... - An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin diseaseGregory M Chronowski
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 95:2534-8. 2002..The relative importance of prognostic factors in patients with early-stage Hodgkin disease remains controversial. The purpose of this study was to evaluate prognostic factors among patients who received chemotherapy before radiotherapy... - Thalidomide for patients with recurrent lymphomaBarbara Pro
Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 100:1186-9. 2004..However, its activity against other lymphoid tumors is unknown. The authors reported their experience with thalidomide in patients with recurrent/refractory non-Hodgkin lymphoma and in patients with Hodgkin disease... - Epigenetic therapy of lymphoma using histone deacetylase inhibitorsMaribel Cotto
University of Puerto Rico, School of Medicine, Hematology Medical Oncology Section, San Juan, Puerto Rico
Clin Transl Oncol 12:401-9. 2010..Several ongoing trials are already exploring HDACi combinations in various types of cancers. Their role in front-line management remains to be determined... - Metabolic abnormalities in lymphomaFernando Cabanillas
Centro de Cancer Auxilio Mutuo, San Juan, Puerto Rico
Clin Lymphoma 3:S32-6. 2002..If these syndromes are identified promptly, they can be corrected. Guidelines for identifying metabolic abnormalities in lymphoma patients, as well as management suggestions, are presented.. - Severe anemia of rapid onset in an inmunocompromised hostEzequiel Rivera Rodríguez
Section of Hematology Oncology, Auxilio Mutuo Cancer Center, San Juan, PR
Bol Asoc Med P R 100:42-6. 2008..The reticulocyte count, bone marrow picture and PCR for DNA for Parvovirus B19 are essential for diagnosis... - Evaluation of Breast Imaging Reporting and Data System Category 3 mammograms and the use of stereotactic vacuum-assisted breast biopsy in a nonacademic community practiceAngela Mendez
Auxilio Mutuo Cancer Center, Hospital Auxilio Mutuo, San Juan, Puerto Rico
Cancer 100:710-4. 2004..Lesions with linear (casting or branching) microcalcifications should not be considered BI-RADS 3 abnormalities... - Quantitative assessment of disease involvement by follicular lymphoma using real-time polymerase chain reaction measurement of t(14;18)-carrying cellsWoo In Lee
Department of Laboratory Medicine, Kyung Hee University College of Medicine, Seoul, Korea
Int J Hematol 79:152-6. 2004..The technique has the potential to be a useful tool in the diagnosis of FL, disease assessment, and prognosticating patients' clinical outcomes... - Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphomaBarbara Pro
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Leuk Lymphoma 47:1818-21. 2006..The combination of fludarabine and paclitaxel has clinical activity in patients with recurrent low-grade NHL... - Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapyGregory M Chronowski
Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Int J Radiat Oncol Biol Phys 55:36-43. 2003.... - Radiotherapy alone for lymphocyte-predominant Hodgkin's diseasePamela J Schlembach
Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030-4009, USA
Cancer J 8:377-83. 2002..Longer follow-up will help to more clearly define the risks of cardiac toxicity and solid tumors that result from involved-field or regional radiotherapy, which appear to be low based on follow-up to date... - Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumorsGeorge Z Rassidakis
Am J Pathol 160:2309-10. 2002 - Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphomaApostolia M Tsimberidou
Department of Lymphoma and Myeloma, University of Texas, M. D. Anderson Cancer Center, Houston 77030, USA
Blood 100:4351-7. 2002..In conclusion, both regimens were associated with high rates of response and survival. ATT was associated with substantially longer FFS, but it was more toxic than FND... - Apoptotic rate in peripheral T-cell lymphomas. A study using a tissue microarray with validation on full tissue sectionsGeorge Z Rassidakis
Department of Hematopathology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
Am J Clin Pathol 118:328-34. 2002..We conclude that the highest ARs in PTCLs are found in enteropathy-type T-cell lymphoma and ALK-positive ALCL, and that AR can be assessed reliably by using a tissue microarray... - Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphomaThomas E Witzig
Division of Internal Medicine and Hematology, Nuclear Medicine, Mayo Clinic and Mayo Foundation, 60 Stabile Building, Rochester, MN 55905, USA
J Clin Oncol 20:2453-63. 2002.... - CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcomeGeorge Z Rassidakis
Department of Lymphoma-Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 20:1278-87. 2002..CONCLUSION: CD20 is expressed by HRS cells in 22% of patients with classical HD but is not associated with different FFS after treatment with equivalent regimens... - Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasoneAndreas H Sarris
Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
Semin Oncol 29:48-55. 2002..The presence of cells with t(14;18) and their numbers are prospectively quantitated in blood and marrow of patients treated with FND plus rituximab to determine their clinical significance both at presentation and during therapy... - Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomasHoon K Lee
Department of Radiation Oncology, Box 97, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, University of Texas, Houston, TX 77030-4009, USA
Leuk Lymphoma 43:1769-75. 2002..Based on the significant risk of relapse at the initial site of disease, different approaches, including chemotherapy with concomitant radiotherapy to doses > or = 45 Gy, warrant investigation... - Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphomaJohn F Seymour
Department of Haematology, The Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
J Clin Oncol 21:2115-22. 2003..This apparent improvement is being further explored in an ongoing randomized trial... - Second malignancies after chemotherapy and radiotherapy for Hodgkin diseaseGregory M Chronowski
Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
Am J Clin Oncol 27:73-80. 2004..08). In an effort to reduce the risk of second malignancies, we have stopped using the alkylating agents nitrogen mustard and procarbazine and elective paraaortic and splenic radiotherapy after chemotherapy... - Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapyCarlo Visco
Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, USA
Leuk Lymphoma 45:2085-92. 2004..0001). In conclusion, high serum IL-10 is independently associated with inferior PFS in patients with HD treated with RT... - Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimenApostolia-Maria Tsimberidou
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 104:345-53. 2005..The overall safety profile for FND was good. However, patients should be monitored for opportunistic infections, and prophylactic antibiotics are recommended, particularly against PCP... - Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosisCarlo Visco
Department of Hematology, Ospedale S. Bortolo, Vicenza, Italy
Eur J Haematol 77:387-94. 2006.... - Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapyBouthaina S Dabaja
Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Cancer 98:1021-8. 2003..CONCLUSIONS: Hyperfractionated WBRT with concurrent BUdR after chemotherapy was found to result in modest disease control but has unacceptable neurotoxicity... - Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemiaDeborah A Thomas
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 77230, USA
Cancer 106:1569-80. 2006..CONCLUSIONS: The addition of rituximab to hyper-CVAD may improve outcome in adult BL or B-ALL, particularly in elderly patients... - Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer CenterQi Liu
Department of Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 24:1582-9. 2006..The apparent plateau in the FFS curve, starting approximately 8 to 10 years from the beginning of treatment, raises the issue of the potential curability of these patients... - Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcomeMarco Herling
Department of Lymphoma and Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 9:2114-20. 2003..CONCLUSIONS: LMP-1 was expressed by HRS cells in 21% of cHL and correlated with mixed cellularity type and higher serum interleukin 10 levels. The presence of LMP-1 was not associated with FFS or OS in uniformly treated patients... - Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significanceKatharina Clodi
St. Anna Kinderspital, Vienna, Austria
Cancer 94:1-5. 2002..Depriving H/RS cells from CD30L and CD40L survival signals by eliminating B cells from HD lesions may be of therapeutic value... - Importance of esophagogastroduodenoscopy in the evaluation of non-gastrointestinal mucosa-associated lymphoid tissue lymphomaBouthaina S Dabaja
Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer J 9:321-4. 2003..DISCUSSION: Routine evaluation of the stomach should be a part of the initial staging work-up of non-GI MALT lymphoma... - Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphomaGeorge Z Rassidakis
Department of Lymphoma-Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 9:2213-20. 2003..Future studies should explore the underlying molecular mechanisms of MUC-1 expression in these tumors and its role as a target for novel therapeutic strategies... - Variations in chemotherapy and radiation therapy in a large nationwide and community-based cohort of elderly patients with non-Hodgkin lymphomaJavier P Berrios Rivera
Division of Epidemiology, University of Texas School of Public Health, Houston, Texas 77030, USA
Am J Clin Oncol 30:163-71. 2007..The objective of this study was to determine the variations in the use of chemotherapy and radiation therapy in a large nationwide and population-based cohort of older patients with non-Hodgkin lymphoma (NHL)... - Quantitative real-time polymerase chain reaction for detection of circulating cells with t(14;18) in volunteer blood donors and patients with follicular lymphomaApostolia-Maria Tsimberidou
Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, USA
Leuk Lymphoma 43:1589-98. 2002..We conclude that patients with follicular lymphoma are more frequently positive, have higher numbers of circulating cells with t(14;18), which exceed upper normal limit more frequently than in volunteer blood donors...